We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Neurocrine Biosciences, Inc. (NBIX) - free report >>
Adherex Technologies Inc. (FENC) - free report >>
Solid Biosciences Inc. (SLDB) - free report >>
GreenTree Hospitality Group Ltd. Sponsored ADR (GHG) - free report >>
Image: Bigstock
New Strong Sell Stocks for December 9th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
GreenTree Hospitality Group Ltd. (GHG - Free Report) develops leased-and-operated and franchised-and-managed hotels. The Zacks Consensus Estimate for its current year earnings has been revised 6.5% downward over the last 30 days.
Neurocrine Biosciences, Inc. (NBIX - Free Report) is a commercial-stage biopharmaceutical company that discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders. The Zacks Consensus Estimate for its current year earnings has been revised 40.5% downward over the last 30 days.
Solid Biosciences Inc. (SLDB - Free Report) is a life science company, engages in developing therapies for duchenne muscular dystrophy. The Zacks Consensus Estimate for its current year earnings has been revised 3.9% downward over the last 30 days.
Fennec Pharmaceuticals Inc. (FENC - Free Report) is a biopharmaceutical company that develops product candidates for use in the treatment of cancer. The Zacks Consensus Estimate for its current year earnings has been revised 5% downward over the last 30 days.
NewAge, Inc. develops, markets, sells, and distributes healthy liquid dietary supplements and ready-to-drink beverages. The Zacks Consensus Estimate for its current year earnings has been revised 31.3% downward over the last 30 days.
View the entire Zacks Rank #5 List.